DDRE-17. INITIAL CLINICAL EXPERIENCE USING OSIMERTINIB IN PATIENTS WITH RECURRENT MALIGNANT GLIOMAS WITH EGFR ALTERATIONS

EGFR alterations are commonly observed in malignant gliomas (MG), especially glioblastomas, making this pathway an appealing therapeutic target. Unlike other EGFR tyrosine kinase inhibitors (TKIs), osimertinib (osi), a third-generation, irreversible EGFR-TKI commonly used to treat EGFR-mutant lung c...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Neuro Oncol
Main Authors: Abousaud, Marin, Faroqui, Naqeeb, Hsu, Fang-Chi, Lesser, Glenn, Strowd, Roy, Ramkissoon, Shakti, Kwatra, Madan, Houston, Kristin Strickland, Carter, Annette, DeTroye, Alisha
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2020
Fag:
Drug Discovery, Drug Resistance
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651426/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.262
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker